Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TTY Biopharm CoROCO:4105 +0.39%83 Interest Coverage is 83.13 as of Mar. 2026, which is 64% above its 10-year median of 50.62. GuruFocus rates ROCO:4105 with a GF Score™ of 83/100 and a GF Value™ of NT$87.56 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 687 Drug Manufacturers companies, TTY Biopharm Co ranks better than 70.16% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. TTY Biopharm Co's
Operating Income
for the
three
months ended in Mar. 2026 was NT$484 Mil. TTY Biopharm Co's Interest Expense for the
three
months ended in Mar. 2026 was NT$-6 Mil.
TTY Biopharm Co's interest coverage for the quarter that ended in Mar. 2026 was 83.13.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for TTY Biopharm Co's Interest Coverage or its related term are showing as below:
ROCO:4105'
s Interest Coverage Range Over the Past 10 Years
Min: 35.98 Med: 50.62 Max: 82.59
Current: 49.14
ROCO:4105's Interest Coverage is ranked better than 70.16% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs ROCO:4105: 49.14
TTY Biopharm Co (ROCO:4105) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
TTY Biopharm Co Interest Coverage Related Terms
TTY Biopharm Co Interest Coverage Historical Data
* Premium members only.
The historical data trend for TTY Biopharm Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
ROCO:4105 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, TTY Biopharm Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTY Biopharm Co Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTY Biopharm Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where TTY Biopharm Co's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TTY Biopharm Co (ROCO:4105) has a Interest Coverage of 83.13 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on TTY Biopharm Co and its competitors. This is 64% above median its historical median of 50.62. Over the past decade, TTY Biopharm Co's Interest Coverage has ranged from 35.98 to 82.59. According to the industry distribution chart, TTY Biopharm Co ranks #205 out of 687 companies in the Drug Manufacturers industry, placing it in the top 29.8%.
Is TTY Biopharm Co's Interest Coverage too high?
TTY Biopharm Co's current Interest Coverage of 83.13 is 64% above median its 10-year median of 50.62. Over the past 10 years, this metric has ranged from a low of 35.98 to a high of 82.59. The Drug Manufacturers industry median Interest Coverage is 12.75. TTY Biopharm Co's value of 83.13 is 552% above this industry median. Based on the distribution chart, TTY Biopharm Co ranks #205 out of 687 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, TTY Biopharm Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, TTY Biopharm Co ranks #205 out of 687 companies for Interest Coverage. This puts TTY Biopharm Co in the upper half of its industry. The industry median Interest Coverage is 12.75. TTY Biopharm Co's value of 83.13 is 552% above this benchmark. Historically, TTY Biopharm Co's own Interest Coverage has ranged from 35.98 to 82.59 over the past decade. While the company's 10-year median is 50.62 vs. the industry median of 12.75, TTY Biopharm Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTY Biopharm Co's current Interest Coverage of 83.13 is 552% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on TTY Biopharm Co and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTY Biopharm Co's current Interest Coverage is 83.13, which is 64% above median its own 10-year median of 50.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.56, compared to a current price of NT$78.10 — trading 10.8% below its estimated fair value. The current Interest Coverage is 83.13, which is 64% above median its 10-year median of 50.62 and 552% above the Drug Manufacturers industry median of 12.75. TTY Biopharm Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current Interest Coverage is 83.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?
Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued.
The current stock price of NT$78.10 is trading 10.8% below its estimated GF Value™ of NT$87.56.
GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.
Key valuation signals for ROCO:4105:
Interest Coverage: 83.13 (64% above median its 10-year median of 50.62)
GF Value™: NT$87.56 vs. price of NT$78.10 (10.8% below fair value)
Industry Position: 552% above the Drug Manufacturers median (#205 of 687)
No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
83GF Score
Get the complete analysis for ROCO:4105
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4105 has been successfully added to your 
